14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $4.18 $5.34 Wednesday, 24th Apr 2024 BCRX stock ended at $4.21. This is 3.88% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 5.74% from a day low at $4.18 to a day high of $4.42.
90 days $4.18 $6.35
52 weeks $4.18 $9.07

Historical BioCryst Pharmaceuticals prices

Date Open High Low Close Volume
Oct 24, 2023 $5.83 $5.89 $5.65 $5.70 2 142 569
Oct 23, 2023 $5.70 $5.94 $5.64 $5.76 1 767 649
Oct 20, 2023 $5.74 $5.98 $5.68 $5.88 1 447 528
Oct 19, 2023 $5.80 $5.82 $5.55 $5.72 1 869 745
Oct 18, 2023 $5.80 $6.01 $5.72 $5.86 1 974 237
Oct 17, 2023 $5.90 $6.18 $5.83 $5.86 3 916 769
Oct 16, 2023 $5.94 $5.98 $5.72 $5.94 2 766 406
Oct 13, 2023 $5.93 $6.07 $5.81 $5.94 2 343 405
Oct 12, 2023 $6.32 $6.35 $5.97 $5.98 2 441 360
Oct 11, 2023 $6.42 $6.45 $6.20 $6.40 1 550 070
Oct 10, 2023 $6.10 $6.42 $6.06 $6.40 1 655 540
Oct 09, 2023 $6.29 $6.34 $6.11 $6.15 1 350 419
Oct 06, 2023 $6.45 $6.57 $6.31 $6.32 1 404 091
Oct 05, 2023 $6.18 $6.63 $6.08 $6.63 2 565 811
Oct 04, 2023 $6.37 $6.42 $6.22 $6.25 1 837 975
Oct 03, 2023 $6.75 $6.77 $6.20 $6.42 2 642 167
Oct 02, 2023 $7.01 $7.06 $6.69 $6.77 2 246 422
Sep 29, 2023 $7.30 $7.34 $7.04 $7.08 1 242 948
Sep 28, 2023 $7.55 $7.64 $7.13 $7.24 2 085 036
Sep 27, 2023 $7.33 $7.54 $7.20 $7.52 2 016 246
Sep 26, 2023 $7.36 $7.59 $7.32 $7.35 1 813 421
Sep 25, 2023 $7.30 $7.57 $7.18 $7.37 2 594 294
Sep 22, 2023 $7.21 $7.37 $7.07 $7.35 1 899 808
Sep 21, 2023 $7.05 $7.25 $6.95 $7.16 1 683 271
Sep 20, 2023 $7.66 $7.70 $7.08 $7.11 1 938 524
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT